Regulation of the cell cycle

The phases of the cell cycle do not simply happen in order because a timer says so. Each transition — from G₁ into S, from G₂ into mitosis — is pushed by a molecular engine: a cyclin-CDK complex. A CDK (cyclin-dependent kinase) is an enzyme that adds phosphate groups to target proteins, and those phosphorylations are what actually launch the next phase. But a CDK is inactive on its own. It only works once it is bound to its partner protein, a cyclin.

That partnership is the whole point. The cyclin is the control knob: the cell makes and destroys cyclins on a schedule, so the amount of cyclin present changes constantly as the cycle turns. When a particular cyclin is abundant, it binds its CDK, the complex becomes active, and CDK activity rises toward a threshold. Cross that threshold and the cell commits to the next phase.

So the single most important thing to hold onto is a chain of dependence: cyclin levels rise → cyclin-CDK activity rises → a transition is triggered. CDK is always there; cyclin is not. The cell controls when to advance by controlling how much cyclin is around. Keep that, and every checkpoint, cyclin curve, and cancer fact in this topic hangs off it.

Regulation is a sequence of cause and effect, not a single event. Walk through what actually happens as the cell decides whether to move forward.

1. Cyclin is synthesized, so its level rises. The cell transcribes and translates a cyclin gene, and cyclin protein accumulates. Its concentration is not fixed — it climbs as the cell approaches a transition. Different cyclins peak at different points in the cycle.
2. Cyclin binds CDK and switches it on. A CDK sitting idle in the cell binds the rising cyclin. Only as this complex forms does the kinase become active. No cyclin bound means no activity, no matter how much CDK protein is present.
3. CDK activity crosses a threshold and triggers the transition. The active complex phosphorylates target proteins that drive the cell into the next phase — DNA replication, or the events of mitosis. The transition fires when activity is high enough, so peaks of cyclin-CDK activity mark the transition points.
4. A checkpoint can veto the advance. Before the transition is allowed, checkpoints test internal and external conditions — is the DNA intact, is it fully replicated, are the chromosomes attached, are growth signals present? If a condition fails, regulators hold the cyclin-CDK engine in check and the cell pauses instead of advancing.
5. Cyclin is destroyed, so its level falls again. Once its job is done, the cyclin is tagged and degraded. Its level drops, the CDK goes quiet, and the cell resets so the next round can be timed the same way. This rise-and-fall is exactly why cyclin levels are never constant.

Read it as one loop: cyclin up → complex active → checkpoint permits → transition → cyclin destroyed → back down. Regulation lives in that oscillation, not in any part sitting at a steady level.

Quick reference card. For each term, read what it is and how it fits the drive-and-control story — rising cyclin, cyclin-dependent kinase, checkpoint veto.

It is tempting to picture cancer cells as normal cells that simply run the cycle at high speed. That framing misses the mechanism. The defining problem in cancer is not that the timer is set fast — it is that the controls have failed. Regulators and checkpoints that normally decide whether to divide stop doing their job, so cells divide when they should not.

Broken checkpoints let bad cells through. A healthy cell reaching the G₁ checkpoint with damaged DNA is supposed to stop, repair, or die. If the checkpoint machinery is mutated, that same damaged cell sails on into S phase and replicates its errors. The cell has not sped up so much as lost its ability to say “not yet.”

p53 is the classic example. The p53 protein senses DNA damage and either pauses the cycle for repair or triggers the cell's self-destruction. When the p53 gene is mutated — one of the most common changes in human cancers — that guardrail is gone. Damaged cells that should have been halted or eliminated keep dividing and pass their damage on.

The engine and the brakes are separate ideas. Cyclin-CDK complexes are the accelerator that drives transitions; checkpoints and regulators are the brakes that decide when it is safe to go. Cancer is fundamentally a brake failure. That is why it is wrong to reduce it to “fast cells” — a cell can divide at an ordinary pace and still be cancerous if it divides without the normal permission.

Why the distinction matters. Regulation is about the decision to proceed. When you explain cancer, name the failure of that decision — a lost checkpoint, a mutated regulator like p53 — rather than an increase in raw speed. Loss of control is the throughline of this whole topic.